Understanding how specific RNA readers affect cancer treatment with radiation and immunotherapy
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
This study is looking at how certain proteins in our cells can help make cancer treatments, like radiation and immunotherapy, work better together, with the hope of finding new ways to help patients who struggle with their current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10889069 on NIH RePORTER |
What this research studies
This research investigates the roles of RNA m6A readers Y1 and Y2 in enhancing the effectiveness of radiation therapy combined with immunotherapy for cancer treatment. By utilizing advanced techniques in RNA modification and bioinformatics, the study aims to uncover how these RNA readers influence immune cell functions in tumors exposed to radiation. The goal is to identify new strategies to overcome treatment resistance and improve patient outcomes in cancer therapy. Patients may benefit from insights that could lead to more effective treatment protocols.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are being treated with radiation therapy and who may benefit from enhanced immunotherapy approaches.
Not a fit: Patients with cancers that do not involve radiation therapy or those who are not candidates for immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies that enhance the effectiveness of radiation therapy combined with immunotherapy.
How similar studies have performed: Other research has shown promising results in combining immunotherapy with radiation, but the specific approach of targeting RNA m6A readers is novel and has not been extensively tested.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Weichselbaum, Ralph R — University of Chicago
- Study coordinator: Weichselbaum, Ralph R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.